The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.

The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi.sup.+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.

The present invention relates to an inhibitor of the Helicobacter pylori (H. pylori) cell purine nucleotide salvage pathway (reserve pathway) for use in the treatment of H. pylori infection and/or the treatment or prevention of a disease associated with this infection, such as gastritis and duodenitis, gastric and duodenal ulcers, as well as gastric cancer and MALT-type lymphoma, as well as pancreatic cancer or neurodegenerative diseases or disorders. The present invention also provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway and at least one pharmaceutically acceptable excipient. The present invention further provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway, at least one pharmaceutically acceptable excipient and at least one additional drug for the treatment of H. pylori infection, selected in particular from an antibiotic, a proton pump inhibitor and a bismuth salt.

The present invention relates to an inhibitor of the Helicobacter pylori (H. pylori) cell purine nucleotide salvage pathway (reserve pathway) for use in the treatment of H. pylori infection and/or the treatment or prevention of a disease associated with this infection, such as gastritis and duodenitis, gastric and duodenal ulcers, as well as gastric cancer and MALT-type lymphoma, as well as pancreatic cancer or neurodegenerative diseases or disorders. The present invention also provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway and at least one pharmaceutically acceptable excipient. The present invention further provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway, at least one pharmaceutically acceptable excipient and at least one additional drug for the treatment of H. pylori infection, selected in particular from an antibiotic, a proton pump inhibitor and a bismuth salt.

Radioprotectant/radiomitigation hybrid material comprising at least one radiation absorbing component and at least one decorporation component. In particular, the hybrid material is composed of melanin and bismuth. The hybrid material may be formed into a pharmaceutical composition, medical device, protective armour, containers, equipment housing and the like. In another embodiment, a method for determining suitable decorporation materials for radioactive substances is also disclosed.

Radioprotectant/radiomitigation hybrid material comprising at least one radiation absorbing component and at least one decorporation component. In particular, the hybrid material is composed of melanin and bismuth. The hybrid material may be formed into a pharmaceutical composition, medical device, protective armour, containers, equipment housing and the like. In another embodiment, a method for determining suitable decorporation materials for radioactive substances is also disclosed.

Radioprotectant/radiomitigation hybrid material comprising at least one radiation absorbing component and at least one decorporation component. In particular, the hybrid material is composed of melanin and bismuth. The hybrid material may be formed into a pharmaceutical composition, medical device, protective armour, containers, equipment housing and the like. In another embodiment, a method for determining suitable decorporation materials for radioactive substances is also disclosed.

Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compositions thereof, utilized for treating for example, kidney disease, diabetes and cardiovascular disease, disorders that are associated with inhibiting the conversion of choline to trimethylamine.

Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compositions thereof, utilized for treating for example, kidney disease, diabetes and cardiovascular disease, disorders that are associated with inhibiting the conversion of choline to trimethylamine.